LISTEN NOW: FDA Crackdown on Tirzepatide and Semaglutide Sources

New Podcast has Dropped!

Original posted at obesity.news/ on Sep 09, 2025

🚨 FDA cracks down on compounded GLP-1 medications, raising questions about the future safety, quality, supply, and cost. In this episode of On The Pen Live, we break down what the FDA’s new “green list” means for patients relying on compounded semaglutide and tirzepatide, including risks like dosing errors, unapproved salt forms, and hospitalizations.

We also cover two massive research moves shaking up the future of obesity and diabetes care:

✅ Novo Nordisk + Novonesis team up on gut microbiome therapies, using probiotics and prebiotics (synbiotics) to prevent obesity and improve blood sugar and cholesterol.

✅ Eli Lilly + Remedium Bio launch a gene therapy partnership that could replace weekly GLP-1 injections with a single, long-acting shot.

PLUS: An exclusive interview with Alicia, cofounder of Claimable, about the class action lawsuit against CVS Caremark for forcing patients to switch from Zepbound to Wegovy. We talk timelines, how to get involved, and what it means for patient choice in obesity treatment.

✨ Sponsored by:

Ro → Safe, doctor-guided access to GLP-1 medications: ro.co/otp

Claimable → Fight back with patient-powered class action tools: claimable.com/otp (Use code OTP10)

Shapa → The numberless scale that changes how you see your health: myshapa.com/otp(Use code OTP30)

📌 If you’re navigating obesity, type 2 diabetes, or GLP-1 access, this is a must-watch.

#GLP1 #Ozempic #Wegovy #Mounjaro #Zepbound #Tirzepatide #Semaglutide #Obesity #Diabetes #WeightLoss

🔗 My Linktree with all resources: LINktr.ee/manonthemounjaro

This article is reader-supported on Substack.

To receive new posts and support my work,

consider becoming a free or paid subscriber.

Subscribe